AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
GlaxoSmithKline Biologicals announces start of human trial of novel HIV vaccine.(Brief Article)
2002 MAR 6 - (NewsRx.com & NewsRx.net) -- GlaxoSmithKline Biologicals (GSK Biologicals) announces the start of the first trial in humans of its recombinant, adjuvanted candidate HIV vaccine - NefTat and gp 120 formulated with the proprietary adjuvant AS02.
The main objectives are to see if the candidate vaccine is safe and whether the human immune system responds to it.
The first human clinical trial of GSK Biologicals' candidate HIV vaccine will be conducted in collaboration with the HIV Vaccine Trials Network (HVTN) in the U.S., following the encouraging results from rhesus monkey efficacy studies and other clinical studies on novel adjuvants. The HVTN is sponsored by the National Institute of Allergy and Infectious Diseases, a component of the U.S. National Institutes of Health.
This Phase I safety and immunogenicity trial will start at up to 11 clinical research centers in the U.S. Healthy male and female adult volunteers who are HIV seronegative and who are at low risk of HIV infection will be enrolled in this clinical trial. The HVTN will begin volunteer recruitment for the trial early 2002.
In earlier ...
- Start of First Clinical Trial With GlaxoSmithKline Biologicals' Novel HIV...
- Press release article from: PR Newswire January 31, 2002 700+ words
...clinical trial of GSK Biologicals' candidate HIV vaccine will be conducted...earlier trials, GSK Biologicals' candidate HIV vaccine has protected...human studies. "GSK Biologicals is committed to developing an HIV vaccine that will prevent...
- GSK Biologicals and IAVI Partner to Develop AIDS Vaccine.
- Press release article from: PR Newswire June 21, 2005 700+ words
...GlaxoSmithKline Biologicals (GSK Biologicals) and the International AIDS Vaccine...After pre-clinical evaluation, GSK Biologicals and IAVI plan to conduct Phase I clinical...that could be much broader. Both GSK Biologicals and IAVI are committed to making any...
- GSK Biologicals aim to triple production by 2010.
- News wire article from: PTI - The Press Trust of India Ltd. April 12, 2006 700+ words
GSK Biologicals aim to triple production by 2010...GlaxoSmithKline Biologicals (GSK Biologicals), an affiliate of the GSK Pharmaceuticals...Limited Chairman D S Parekh said the GSK Biologicals delivered 1.2 billion vaccine...
- Corixa and GSK Biologicals Announce Plans to Initiate a Human Clinical Study in...
- Press release article from: Business Wire January 14, 2004 700+ words
...Biologicals GlaxoSmithKline Biologicals (GSK Biologicals), the world's leading vaccine...research, development and production. GSK Biologicals employs more than 1,000 research...worldwide. Last year, an average of 25 GSK Biologicals vaccine doses per second were delivered...
- GSK has also signed a cooperation agreement to form a joint venture, through...
- Magazine article from: Chemistry and Industry Eisberg, Neil December 22, 2008 700+ words
GSK has also signed a cooperation agreement to form a joint venture, through GSK Biologicals, with China's Shenzhen Neptunus Interlong BioTechnique for the co-development of seasonal influenza and pre-pandemic/ pandemic...
- Antigenics extends deal with GSK Biologicals.(Antigenics Licensing agreements...
- Newspaper article from: Pharma Marketletter July 17, 2006 700+ words
New York, USA-based Antigenics says that it has signed expanded license and supply agreements for the use of QS-21 Stimulon adjuvant with GlaxoSmithKline Biologicals, a vaccine division of UK drug major GlaxoSmithKline. QS-21 is a key component included in several of GSK's proprietary adjuvant
- Cobra signs agreement with the International AIDS Vaccine Initiative and...
- Magazine article from: Pharmaceutical Processing June 1, 2006 700+ words
...International AIDS Vaccine Initiative (IAVI) and GlaxoSmithKline Biologicals S.A. (GSK Biologicals), for process development and manufacturing of two HIV vaccine candidates for evaluation in clinical trials. The vaccine candidates incorporate...
- AIDS Action Observes HIV Vaccine Awareness Day: Reason to Hope.
- Newspaper article from: AIDS Vaccine Week June 1, 2009 700+ words
...tragic reality, the ongoing search for an HIV vaccine gives us reason to hope. The HIV vaccine research field continues to advance, and...year of promise. Today, on May 18th, HIV Vaccine Awareness Day, AIDS Action urges everyone...
Source: HighBeam Research, GlaxoSmithKline Biologicals announces start of human trial of novel...